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ttp://dx.doi.org/10.1016/j.ajpath.2013.10.011Globoid cell leukodystrophy is a lysosomal storage disease characterized by the loss of galactocere-
brosidase. Galactocerebrosidase loss leads to the accumulation of psychosine and subsequent oligo-
dendrocyte cell death, demyelination, macrophage recruitment, and astroglial activation and
proliferation. To date, no studies have elucidated the mechanism of glial cell activation and cytokine
and chemokine up-regulation and release. We explored a novel explanation for the development of the
pathological changes in the early stages of globoid cell leukodystrophy associated with toll-like re-
ceptor (TLR) 2 up-regulation in the hindbrain and cerebellum as a response to dying oligodendrocytes.
TLR2 up-regulation on microglia/macrophages coincided with morphological changes consistent with
activation at 2 and 3 weeks of age. TLR2 up-regulation on activated microglia/macrophages resulted in
astrocyte activation and marked up-regulation of cytokines/chemokines. Because oligodendrocyte cell
death is an important feature of globoid cell leukodystrophy, we tested the ability of TLR2 reporter cells
to respond to oligodendrocyte cell death. These reporter cells responded in vitro to medium conditioned
by psychosine-treated oligodendrocytes, indicating the likelihood that oligodendrocytes release a TLR2
ligand during apoptosis. TLRs are a member of the innate immune system and initiate immune and
inﬂammatory events; therefore, the identiﬁcation of TLR2 as a potential driver in the activation of
central nervous system glial activity in globoid cell leukodystrophy may provide important insight into
its pathogenesis. (Am J Pathol 2014, 184: 382e396; http://dx.doi.org/10.1016/j.ajpath.2013.10.011)Supported in part by the National Center for Research Resources, NIH,
grants P51 OD011104 (Tulane National Primate Research Center) and T32
RR021309 (E.S.) and Tulane University grants.Globoid cell leukodystrophy (GLD; Krabbe’s disease) is an
autosomal recessive lysosomal storage disorder. It affects
approximately 1 in 100,000 children born each year and often
leads to mortality by 2 years of age. GLD results from the
lack of metabolic enzyme galactocerebrosidase (GALC).1 In
the absence of GALC, galactocerebroside (GalCer) un-
dergoes alternative catabolism into galactosylsphingosine
(alias psychosine) and a fatty acid instead of normal catab-
olism into its component parts, galactose and ceramide.2
Galactosylsphingosine has been shown to cause the termi-
nal pathological changes in the central nervous system (CNS)
of individuals affected by GLD: globoid cell formation,2,3
astroglial cytokine and chemokine secretion,4e8 and oligo-
dendrocyte death and demyelination.9e14 In addition to these
pathological changes, it is established that monocytes/mac-
rophages are recruited to the CNS early in the disease processstigative Pathology.
.and continue to mobilize to the brain until the late stages of
disease.15,16
Little is understood, however, about the mechanisms un-
derlying these events, or which cells are involved in eliciting
the initial pathological changes.7,17,18 This study investigated
the mechanisms involved in monocyte/macrophage recruit-
ment and cytokine/chemokine up-regulation and secretion, as
well as which cell types are the earliest to undergo inﬂam-
matory cascades leading to terminal disease.
Inﬂammatory cytokines are up-regulated as a consequence
of activation of the innate immune response.19e22 Given the
connection, it is logical to link the innate immune response to
Early Events in GLDinﬂammation in globoid cell leukodystrophy. Psychosine is a
derivative of b-galactosylceramide and a ganglioside;
therefore, it could potentially serve as a toll-like receptor
(TLR) ligand and induce the up-regulation of cytokine/che-
mokine secretion and monocyte/macrophage recruitment
through the initial activation of a TLR.
TLRs are most commonly associated with recognition of
speciﬁc, exogenously derived recognition of microbial patterns.
Examples of these patterns are lipopolysaccharide, peptido-
glycan, lipoarabinomannan, and double-stranded RNA.23
However, TLRs also have known roles in exacerbating in-
ﬂammation and inﬂammatory proﬁles in the brains of other
neurodegenerative and demyelinating diseases, such as experi-
mental autoimmune encephalitis (murine model for multiple
sclerosis),24,25 amyotrophic lateral sclerosis,26 and Alzheimer
disease.27,28 Investigating whether TLRs play a role in the initi-
ation of inﬂammatory signaling pathways in the brains of
twitcher mice (the murine model for globoid cell leukodystro-
phy) is important to understanding how inﬂammation in GLD is
initiated. Elucidating how inﬂammation is induced in the course
of disease will lead to more complete knowledge of the patho-
genesisofGLDand the identiﬁcationofnovel therapeutic targets.
To date, few studies have been performed that investigate
the early events in GLD that lead to the terminal changes
associated with the disease. It is known that globoid cell
appearance and demyelination occur caudally to rostrally in
the twitcher brain,29 but the mechanism has not been studied.
Our hypothesis was that TLR up-regulation on perivascular
macrophages and/or microglia early in the disease initiates
cytokine production and monocyte/macrophage recruitment to
brains of affected individuals. After activation, microglia and
macrophages activate neighboring astrocytes, whichmarkedly
exacerbate cytokine/chemokine secretion and inﬂammation.
This study identiﬁes early morphological changes in resident
CNS glial cells and the innate immune system that explain, at
least in part, how cells become activated, up-regulate cyto-
kines/chemokines, and recruit monocytes/macrophages.
Materials and Methods
Animals
A total of 98 mice (twitcher and age-matched controls)
were euthanized at the ages of 2, 3, 4, and 5 weeks. Each
experiment used at least three animals per group and timeTable 1 List of Antibodies Used in Immunoﬂuorescence
Antigen Cell type Source
TLR231,32 NA Abcam (Cambridge, MA)
GFAP Astrocyte Sigma (St. Louis, MO)
S100 Glial, ependymal Sigma
IBA-1 Microglia Wako (Richmond, VA)
NeuN Neuron Chemicon (Billerica, MA)
F4/80 Microglia/macrophage Santa Cruz (Dallas, TX)
Glut-1 Endothelial cells Abcam
NA, not applicable.
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brain and cerebellum/brainstem (hindbrain). Twitcher and
age-matched wild-type controls were genotyped using an
established molecular beacon PCR assay.30 All procedures
were performed according to an animal protocol approved by
the Tulane Institutional Animal Care and Use Committee.
Tissue Dissection and Handling
After euthanasia via CO2 asphyxiation, the heads were
removed with a scalpel blade and the skull was removed from
the meninges with bone rongeurs. The brain was removed, and
placed into an acrylic brain matrix with 1-mm divisions. The
forebrain, immediately caudal to the olfactory bulbs, was
trimmed coronally at 3 mm, and the entire cerebellum and
underlying brainstem were taken together and trimmed along
the sagittal midline. Tissues were: i) placed into 1 mL of
RNAlater (Life Technologies, Grand Island, NY), ii) snap
frozen on dry ice and maintained at 80C, or iii) ﬁxed in 2%
paraformaldehyde for 4 hours. After ﬁxation, the sections were
washed in PBS and cryoprotected with 30% sucrose for 3 to 5
days. All cryoprotected sections were embedded in optimal
cutting temperature compound (Tissue Tek, Torrance, CA) and
divided into sections (16 mm thick) for confocal microscopy.
For parafﬁn-embedded tissues, mice were euthanized via
CO2 asphyxiation and perfused with sterile PBS through the
left ventricle of the heart. Tissues were removed and ﬁxed for
24 hours to 1 week in 10% neutral-buffered formalin and
subsequently embedded in parafﬁn. Parafﬁn-embedded tissues
were divided into sections (5 mm thick) and mounted onto glass
slides for immunohistochemical (IHC) or histochemical stains.
Confocal Microscopy
Optimal cutting temperature compoundeembedded forebrain
and hindbrain specimens were divided into sections (16 mm
thick) for confocal microscopy. Immunodetection of TLR2 in
combination with the cell-speciﬁc antibodies indicated in
Table 1 and Topro-3 (model T3605; Life Technologies) to
label nuclei was performed as described previously.33 Brieﬂy,
tissues were blocked with PBS containing 10% normal goat
serum and 0.2% ﬁsh skin gelatin (Sigma-Aldrich, St. Louis,
MO), incubated with the primary antibody for 1 hour, washed
with PBSeﬁsh skin gelatineTriton X-100 (Sigma-Aldrich),
and ﬁnally incubated for 1 hour with secondary antibodiesAntibody type Working dilution
Rb polyclonal 1:50
Ms IgG1, labeled with Cy3 1:200
Rb polyclonal 2.5 mg used with zenon
Rb polyclonal 2.5 mg used with zenon
Ms IgG1 1:10
Rat IgG1 1:10
Ms IgG1 1:40
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Snook et alagainst the appropriate primary antibody for 1 hour. TLR2 was
always labeled with a secondary antibody tagged with Alexa
488 (Molecular Probes/Life Technologies, Grand Island, NY),
whereas all cell-speciﬁc antibodies [glial ﬁbrillary acidic pro-
tein (GFAP), ionized calcium-binding adapter protein (IBA)-1,
S100, and neuronal nuclear antigen] were labeled with a sec-
ondary antibody tagged with either Cy3 (Sigma-Aldrich) or
Alexa 568 (Molecular Probes/Life Technologies). Sections
were ﬁxed in 4% paraformaldehyde for 5 minutes after staining
with the secondary antibody. When two primary rabbit poly-
clonal antibodies were used together (ie, TLR2 and IBA-1), 2.5
mg of the cell-speciﬁc antibody was prelabeled with Zenon
labeling reagents (Molecular Probes/Life Technologies), ac-
cording to the manufacturer’s instructions. Slides were moun-
tedwith an anti-quenchingmedium containingMOWIOL 4-88
(Calbiochem/EMDMillipore, Billerica,MA), glycerol (Sigma-
Aldrich), and 2.5% DABCO Mountant (Sigma-Aldrich).
All images were captured with a Leica SP2 true confocal
system (Leica Microsystems, Buffalo Grove, IL) at 40
magniﬁcation with an HCL planar apochromatic confocal
system 2 oil lens objective. The numerical aperture of the lens
objective was 1.3. All confocal microscopy was performed at
68C to 70C. Leica acquisition software was used to capture
the confocal images. Volocity version 5 (Perkin Elmer,
Boston, MA) and Adobe Photoshop CS5 were used for more
in-depth image analysis and counting cells manually.
Image Analysis
To establish IBA-1 and GFAP up-regulation in the pro-
gression of disease, mean ﬂuorescent intensity (MFI) was
measured from 10 random, nonoverlapping ﬁelds from three
twitcher and three normal mice at 2, 3, and 5 weeks of age.
MFI was calculated with ImageJ software version 10.2
(NIH, Bethesda, MD) after thresholding was applied equally
to each image to correct for apparent background and allow
for determination of patterns in staining characteristics.
Averages and SDs of MFI were calculated and reported. The
same process was performed for glial nodule analysis within
a diameter of >110 mm, which was determined to encom-
pass the entire nodule in all cases examined.
To analyze TLR2 expression, 10 random, nonoverlapping
ﬁelds from the forebrain and hindbrain were analyzed for three
twitcher and three normal animals at 2, 3, and 5 weeks of age.
Images were converted to three-dimensional (3D) images
using Volocity software version 5, which allowed visualiza-
tion of staining characteristics to determine whether colocali-
zation was present for each antibody combination. Images
were thresholded and analyzed. Cells were counted as positive
if the signal was present on or near a stained nucleus, or if the
staining had distinct cellular morphological characteristics.
Light Microscopy
3,30-Diaminobenzidine/hematoxylin, luxol fast blue (for
myelin), and PAS (for polysaccharides) stained slides were384analyzed by standard light microscopy. Images were
captured with a spectral camera (CRI-Nuance, Lincolnshire,
UK), and the original red-green-blue colorspace image was
spectrally unmixed to yield images with high contrast.34
Quantiﬁcation of Astrocyte Morphological Features
All samples were coded and analyzed randomly by a
researcher (H.A.S.) blinded to animal number and condition.
Images of nonoverlapping ﬁelds in hindbrain and cerebellar
sections were captured by ﬂuorescence microscopy using
a Leica confocal microscope at 40 magniﬁcation and
analyzed using Neurolucida software version 10.02 (MBF
Bioscience, Williston, VT). A total of 28 astrocytes around or
in a nodule within the twitcher hindbrain, 67 astrocytes from
areas away from nodules within the hindbrain, and 26 as-
trocytes from control mice with well-deﬁned cell bodies and
processes were chosen for further analysis. The cells selected
were fully intact and did not have processes that touched
the edges of the ﬁeld. The resulting ﬁles were analyzed
with Neurolucida Explorer (MBF Bioscience), generating
morphological data, including cell area, branching points
(nodes), arbor length, and volume.
qPCR Analysis
Four twitcher and four normal mice per time point were
euthanized at 2, 3, 4, and 5 weeks of age. Each section of
brain was placed into RNAlater for preservation. For RNA
extraction, the forebrain and hindbrain were halved and
homogenized using standard TRIzol extraction (catalog no.
15596026; Life Technologies). RNA concentrations were
measured with a spectrophotometer, and 2 mg of RNA was
used for cDNA synthesis with random hexamers. TaqMan
primers and probes from Life Technologies were used to
quantify mRNA expression at each time point in the fore-
brain or hindbrain. The following primers and probes were
used for real-time PCR: TLR1 (Mm00446095_m1), TLR2
(Mm00442346_m1), TLR3 (Mm0068112_m1), TLR4
(Mm00445273_m1), TLR5 (Mm00546288_s1), TLR6
(Mm02529782_s1), TLR7 (Mm00446590_m1), TLR8
(Mm01157262_m1), and TLR9 (Mm00446193_m1). Hy-
poxanthine guanine phosphoribosyl transferase (HPRT) 1
was used as the endogenous control (Mm00446968_m1).35
Real-time PCR was performed in an Applied Biosystems
7900 HT thermocycler (Life Technologies), and the
accompanying software automatically selected the appro-
priate CT values. DDCT values for use in fold change
calculation were calculated using the following formula:
ðCT; TARGET CT; HPRT1ÞTWITCHER
 ðCT; TARGET  CT; HPRT1ÞNORMALZDDCT ð1Þ
Fold change was determined with the formula 2-DDCT,
and the SD was calculated based on the ﬁnal fold change
values.36ajp.amjpathol.org - The American Journal of Pathology
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Human embryonic kidney (HEK)-blue (catalog no. hkb-
mtlr2; Invivogen, San Diego, CA) murine (m)TLR2 (HEK-
TLR2) overexpressing cells and HEK-blue null2 (catolog
no. hkb-null2; Invivogen) (HEK-null) cells were propagated
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) with
10% fetal bovine serum, 10 U penicillin, 10 mg strepto-
mycin, and normocin, as per the manufacturer’s in-
structions. HEK-TLR2 cells were placed in medium
containing selective antibioticsdhygromycin, blasticidin,
and zeocindthat induce expression of murine TLR2, CD14,
and secreted alkaline phosphatase fused to ﬁve NF-kB and
activator protein (AP)-1 binding sites. The HEK-null cells
were placed in medium containing zeocin, which induces
expression of secreted alkaline phosphatase fused to NF-kB
and AP-1 binding sites. One packet of Quanti-blue (Inviv-
ogen) was mixed with 100 mL of ultrapure water and vac-
uum ﬁltered through a 0.22-mm ﬁlter.
M03.13 cells (immortalized oligodendrocyte cell line)
were cultured in high glucose (4.5 mg/dL) DMEM and 10%
fetal bovine serum with no sodium pyruvate at 37C and
5% CO2. Oligodendrocyte differentiation was induced by
plating the cells onto 6-well dishes at approximately 1  106
cells/mL and cultured for 3 days in serum-free DMEM with
100 nmol/L phorbol 12-myristate 13-acetate. After differ-
entiation, the cells were treated with psychosine at 100, 50,
20, 10, 5, and 0 mg/mL. Medium (200 mL) was removed at
24, 48, and 72 hours, and frozen at 80C for use in the
TLR2 reporter assay.
TLR2 Reporter Assay
The TLR2 reporter assay demonstrates completion of the
TLR2 signaling pathway based on alkaline phosphatase
production when stimulated with deﬁned agents. Cell sus-
pensions (180 mL) containing approximately 280,000 HEK-
TLR2 or HEK-null cells per milliliter were incubated in
96-well plates for 20 hours with 20 mL of 1 mg/mL of tumor
necrosis factor (TNF)-a, 100 ng/mL of PAM3CSK4, or 10 ng
to 10 mg/mL psychosine. Supernatant (20 mL) was added to
180 mL of Quanti-blue reagent in 96-well plates and incu-
bated at 37C for 3 hours. Color change was measured with a
Biotek Epoch (Winooski, VT) spectrophotometer at 655 nm.
Alternatively, 20 mL of supernatant from psychosine-treated
oligodendrocytes was added to 180 mL of HEK-mTLR2 or
HEK-null2 cells and incubated for 20 hours. Analysis was
performed as described.
Multiplex Bead-Based Cytokine Assay
Flash-frozen brain sections of four twitcher and three normal
mice at 2, 3, 4, and 5 weeks of age were crushed with mortar
and pestle on dry ice. A portion of ground tissue was weighed
and added to 20 volumes of PBS with 0.2% NP-40 and
protease/phosphatase inhibitors and ultrasonicated on iceThe American Journal of Pathology - ajp.amjpathol.orgbrieﬂy until dissolved. Samples were centrifuged twice at
10,000  g for 10 minutes to remove debris. The supernatant
was aliquoted and stored at80C. Protein was quantiﬁedwith
a bicinchoninic acid protein measurement kit. Samples were
thawed and prepared for a cytokine kit according to the man-
ufacturer’s instructions. Using this kit, 32 individual cytokines
and chemokines were analyzed for up-regulation, including
eotaxin [chemokine ligand (CCL) 11], granulocyte colony-
stimulating factor (CSF), granulocyte-macrophage CSF,
interferon (IFN)-g, IL-1a, IL-b, IL-2, IL-3, IL-4, IL-5, IL-6,
IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-
17, interferon g-induced protein (IP)-10 (CXCL10),
keratinocyte-chemoattractant (CXCL1), leukemia inhibitory
factor, lipopolysaccharide-induced CXC chemokine, macro-
phage CSF, monocyte chemotactic protein-1 (CCL2), mono-
kine induced by g interferon (CXCL9), macrophage
inﬂammatory protein (MIP)-1a (CCL3), MIP-1b (CCL4),
MIP-2, regulated on activation normal T cell expressed and
secreted (CCL5), TNF-a, and vascular endothelial growth
factor. After analysis on a Bio-Rad bioplex analyzer, samples
were normalized according to protein concentrations.
Normalized values were used to quantify levels of cytokine
expression.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism,
version 5 (GraphPad Software, La Jolla, CA). For the
quantitative PCR (qPCR) assay, data that conformed to
normal distribution were analyzed with a Student’s t-test.
Data that were not normally distributed were analyzed with
a Wilcoxon signed rank test. In all other analyses, data were
analyzed by one-way analysis of variance and Tukey’s post
hoc test if normally distributed. If data were not normally
distributed, they were analyzed with a Kruskal-Wallis test
with Dunn’s post hoc multiple comparison test to determine
signiﬁcance between groups. Results are expressed as
means  SD. Signiﬁcance was set at P < 0.05.
Results
IBA-1 and GFAP Expression Increases at 3 Weeks of
Age
Microglia and, to a lesser extent, astrocytes are considered
able to respond to innate immune system stimuli. To assess
whether microglia or astrocytes are activated ﬁrst, IBA-1
(microglia) and GFAP (astrocytes) immunoreactivities were
examined at 2, 3, and 5 weeks of age. GFAP is a marker of
astroglial activation, whereas IBA-1 identiﬁes resting and
activated microglia37; however, microglia demonstrate spe-
ciﬁc morphological changes when activated.38 At 2 weeks of
age, IBA-1þ cells showed a moderate increase in the thick-
ness and number of processes extending from the cell body
compared with age-matched controls (Figure 1). By 3 weeks
of age, microglial activation was common, characterized by385
Figure 1 Microglia exhibit morphological evidence of activation in the
2-week-old twitcher hindbrain. Confocal images were captured. Original
magniﬁcation, 40. Images are representative of three normal and three
twitcher mouse hindbrains immunostained for microglia (IBA-1, green), as-
trocytes (GFAP, red), and cell nuclei (Topro-3, blue). A: Arrowhead identiﬁes
restingmicroglia in a normalmouse. The restingmicroglia has a small cell body
and few, thin processes extending from the cell body. B: Activated microglial
cells (arrowhead), characterized by enlarged cell bodies with numerous hy-
pertrophied processes. Immunoreactivity for GFAP is minimal at this time
point in normal and twitcher mice. Scale barZ 50 mm.
Figure 2 Whole ﬁeld analysis of IBA-1 (black bars) and GFAP (white
bars) MFI demonstrated signiﬁcant increases at 3 weeks of age in the
twitcher (twi) mouse hindbrain. Ten random, 40 ﬁelds were captured and
analyzed with ImageJ software version 10.2 from three twitcher and three
normal (N) mice at each time point. MFI was calculated and averaged
among all 30 images in each group. A: No signiﬁcant difference between
MFI for IBA-1 and GFAP was found between twitcher mice and age-matched
control mice at 2 weeks of age. B: At 3 weeks of age, signiﬁcant differences
between the MFI for IBA-1 and GFAP were observed in the hindbrain but
not the forebrain. C: At 5 weeks of age, signiﬁcant differences between the
MFI for IBA-1 and GFAP were observed between twitcher mice and normal
mice in both the hindbrain and forebrain. FB, forebrain; HB, hindbrain.
Error bars Z SD. **P < 0.01, ***P < 0.001.
Snook et alaggregates of ameboid microglia forming discrete nodules
within the neuropil. By using MFI as an arbitrary unit of
measure, there was no signiﬁcant change in IBA-1 or GFAP
immunoreactivity in the twitcher mouse hindbrain at 2 weeks
of age versus the normal hindbrain (Figure 2A). Beginning at
3 weeks of age, IBA-1MFI in normal mice began to diminish
signiﬁcantly compared with age-matched twitcher mice
(Figure 2B). At 5 weeks of age, IBA-1 MFI remained at
similar expression levels as at 3 weeks of age; however,
IBA-1 in normal mice was markedly diminished, resulting in
a signiﬁcant difference in both the hindbrain and forebrain
(Figure 2C). GFAP immunoreactivity did not increase
signiﬁcantly over age-matched control mice until 3 weeks of
age in the hindbrain of twitcher mice, and continued to in-
crease in the twitcher brain through 5 weeks of age
(Figure 2C). Similar to IBA-1, GFAP MFI diminished in
normal mice over time in the brains of affected mice
(Figure 2C). These results demonstrated morphological evi-
dence of microglial activation before the activation of
neighboring astrocytes as early as 2 weeks of age in the
hindbrain. In normal mice, IBA-1 immunoreactivity appears
to decrease over time as microglia begin to assume a quies-
cent state. In twitcher mice, microglia remained activated.
Formation of Glial Nodules and Activation of
Surrounding Astrocytes
A novel pathological alteration was identiﬁed while exam-
ining images for IBA-1 and GFAP immunoreactivity.
Microglia formed prominent, discrete nodules that were often
surrounded by hypertrophied astrocytes (Figure 3A). At 2
weeks, these nodules occurred at a frequency of 0.5 per 0.14
mm2 (40 ﬁeld); the age-matched control mice demonstrated
no evidence of glial nodules (Figure 3A). At 3 weeks, the
nodules became more frequentdapproximately 1.5 per 0.14
mm2dwith numerous GFAPþ astrocytes surrounding them
and interdigitating with the IBA-1þ microglia. No evidence386 ajp.amjpathol.org - The American Journal of Pathology
Early Events in GLDof microglial or astroglial activation or nodule formation of
any type was evident in age-matched control mice. By 5
weeks of age, nearly all microglia in twitcher mice appeared
amoeboid; however, the activated astrocytes no longer
appeared to be centered on microglial nodules. Instead,
the GFAPþ cells appear to be diffusely activated with no
clear, consistent interaction with nearby microglial cells.
Age-matched controls for each group demonstrated
morphological characteristics consistent with resting micro-
glia and rare activated astrocytes. Based on high-resolution
3D confocal images, the microglial nodules were individualThe American Journal of Pathology - ajp.amjpathol.orgcells aggregated together rather than a single syncytial
microglia surrounded by astrocytes (Figure 3B).
By using three twitcher and three normal mice per age
group, MFI was measured in 110-mm-diameter areas
centered onmicroglial nodules for both IBA-1 and GFAP at 2
and 3 weeks of age. At 2 weeks, there was a signiﬁcant in-
crease in MFI within the nodule and surrounding space
compared with randomly chosen 110-mm-diameter locations
within twitcher hindbrains and hindbrains of age-matched
controls. GFAP did not demonstrate a meaningful change in
MFI within any 110-mm-diameter area in any mice, whether
around a nodule or randomly chosen in the hindbrain
(Figure 4A). In 3-week-old twitcher mice, a signiﬁcant
elevation in the MFI of IBA-1 was noted in twitcher glial
nodules when compared with randomly selected areas in
twitcher hindbrains and with random areas in the age-
matched controls (Figure 4B). However, the 3-week-old
twitcher mice began to show a signiﬁcant elevation of GFAP
MFI around the glial nodules when compared with randomly
located areas in twitcher hindbrains and age-matched con-
trols. In addition, GFAP MFI was signiﬁcantly higher in
twitcher hindbrains when compared with randomly located
areas within normal mice. These data demonstrated a sig-
niﬁcant, quantiﬁable elevation in IBA-1 immunoreactivity in
local regions within hindbrains before activation of sur-
rounding astrocytes, indicating that microglia are likely the
ﬁrst cells to demonstrate morphological and immunopheno-
typic markers of activation in the twitcher brain. Astrocytes
were subsequently activated, ﬁrst in association with glial
nodules and then diffusely throughout the brain.
Astrocytes Demonstrate Morphological Changes
Associated with Activation in Twitcher Mice
Based on the MFI data, 3-week-old hindbrains were used to
further quantify astroglial changes in twitcher and control
brains. Fluorescent images of astrocytes were imported into
Neurolucida and analyzed for process lengths (cell arbor), cell
body area, the number of processes extending from the bodies,
the number of tips associated with cell bodies, and the number
of bifurcations of each process. Tracings of astrocytes from
control and affected mice demonstrated numerous changes.
The sum of astrocyte process lengths (cell arbor) was
increased greater than twofold in astrocytes near glial nod-
ules and nearly twofold in astrocytes away from glialFigure 3 Development of glial nodules and astrogliosis in the hindbrain
of twitcher mice. A: Confocal images. Original magniﬁcation, 40. Devel-
opment of glial nodules and astrogliosis from weeks 2 to 5 compared with
age-matched control mice. Arrowheads indicate glial nodules. Glial nodules
(IBA-1, green) are seen as early as 2 weeks of age and then increase in
frequency. Associated with the glial nodules are numerous astrocytes (GFAP,
red) with thickened processes (astrogliosis). Over time, astrogliosis becomes
diffuse. Scale barZ 50 mm. B: A representative 3D image from the hindbrain
of a 3-week-old twitcher mouse captured with Volocity software version 5.
Original magniﬁcation, 63 with 2 digital zoom. Images depict a central
microglial aggregate (green) surrounded by interdigitating, hypertrophied
astrocytes (red). Each square is 37.5  37.5 mm.
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Figure 4 Targeted MFI analysis of glial nodules shows that microglial
activation precedes astroglial activation. MFI for IBA-1 (black bars) and GFAP
(white bars) was measured within a 110-mm-diameter circular area centered on
the microglial aggregate. A: At 2 weeks of age, 110-mm-diameter circles around
glial nodules demonstrated signiﬁcant increases in IBA-1 MFI compared with
randomly chosenareas in twitcher (twi) brains and randomly chosenareaswithin
normal (N) brains. B: At 3 weeks of age, 110-mm-diameter circles around glial
nodules demonstrated signiﬁcant increases in IBA-1 compared with randomly
chosen areas in twitcher brains and normal brains. GFAP also demonstrated
signiﬁcant increases within 110-mm circles compared with randomly chosen
areas in twitcher brains andnormal brains. In addition, randomly chosenareas in
twitcher brains also demonstrated signiﬁcant elevations in MFI of GFAP when
compared with randomly located areas in normal brains. Results are means of
MFI across all nodules for area selected. CeH: Astrocyte cell bodies and den-
drites were tracedwith Neurolucida to determine characteristics associatedwith
hypertrophy. In this case, all characteristics demonstrated signiﬁcant changes
between the normal mouse hindbrain and twitcher mouse hindbrain. Cell body
area was signiﬁcantly larger between astrocytes around glial nodules and away
from glial nodules within twitcher mouse hindbrains. Error bars Z SD. A.U.,
arbitrary unit. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Similarly, by using the diameter of the astrocyte processes,
frustra were generated in Neurolucida to determine arbor
volume of astrocyte processes. These data also demon-
strated signiﬁcant increases between astrocytes near glial
nodules and away from glial nodules, between astrocytes
near glial nodules and astrocytes in normal control mice,
and between astrocytes away from glial nodules and astro-
cytes in normal control mice (Figure 4D).
The area of the astrocyte cell bodies was measured in
Neurolucida version 10.02 (MBF Bioscience). There was a
signiﬁcant increase in cell body area in astrocytes of twitcher
mice hindbrains compared with age-matched controls
(Figure 4E). Astrocytes near glial nodules had signiﬁcantly
enlarged bodies compared with astrocytes away from nodules
and normal astrocytes. In addition, astrocytes away from glial
nodules had signiﬁcantly enlarged bodies compared with
normal astrocytes (Figure 4E).
The number of processes leaving the cell body, bifurcations
of processes, and tips of processes were all increased in
twitcher mice compared with controls. Astrocytes in twitcher
mice (both near and away from glial nodules) demonstrated
increased mean numbers of processes (dendrites) extending
from their cell bodies when compared with astrocytes in
control mice (Figure 4F). Likewise, astrocytes in twitchermice
(near and away from glial nodules) demonstrated signiﬁcant
increases in bifurcations and tips compared with astrocytes in
control mice (Figure 4, G and H).
Collectively, the data show astrocytes in twitcher mice have
more processes, longer processes, and increased cell sizes
compared with age-matched controls. All of the astrocyte
morphological measurements support the hypothesis that glial
nodules likely activate neighboring astrocytes. Althoughmany
of the parameters measured are not signiﬁcantly elevated be-
tween astrocytes near glial nodules and those away from glial
nodules, there is still an increasing trend in all parameterswhen
astrocytes are near glial nodules. This could indicate that as-
trocytes near glial nodules are activated ﬁrst, and subsequently
activate neighboring astrocytes until astrocytes are diffusely
activated near the terminal time point of 5 weeks old.
TLR1 and TLR2 Expression Levels Correlate with
Microglial Activation
Based on data from previous studies indicating that gan-
gliosides can induce TLR signaling,39e41 we examined the
expression of TLRs 1 to 9 in the brain using qPCR. We
found a statistically signiﬁcant increase in TLR1 and TLR2
in the hindbrain at 2 weeks of age. In the forebrain, there
was no signiﬁcant change in TLRs 1 to 9 at 2 weeks of age
compared with age-matched control mice. At 3 weeks of
age, TLR2 demonstrated a ninefold change compared with
age-matched control normal mice and remained markedly
elevated through the life of the twitcher mice. In the fore-
brain, TLRs 1 and 2 began to increase at 3 weeks of age,
mirroring the pattern in the hindbrain. By 5 weeks of age,ajp.amjpathol.org - The American Journal of Pathology
Early Events in GLDTLR2 was markedly increased over normal mice in the
forebrain. TLRs 7 and 8 showed increased expression, but
only late in the disease process in the hindbrain (Figure 5A).
Microglia and Macrophages Express TLR2
To determine which cells expressed TLR2, multilabel
confocal microscopy was performed. At 3 weeks of age, most
TLR2-expressing cells were located around vessels andFigure 5 TLR2 mRNA exhibited signiﬁcant up-regulation at 2 weeks of age,
mRNA levels of TLRs 1 to 9 in twitcher versus normal mice. A: Four twitcher and fo
TLRs 1 to 9 at weekly intervals between 2 and 5 weeks of age. B: Confocal micros
week-old twitcher hindbrain. Arrowhead indicates TLR2þ/IBA-1þ cells. C: Five-wee
IBA-1þ cell. Arrowheads indicate TLR2þ cells. D: Five-week-old twitcher hindbr
hindbrain. Arrowheads indicate TLR2þ/S100þ cells. F: Five-week-old twitcher for
week-old normal mouse hindbrain. TLR2 immunoreactivity is not present. IBA-1þ
hindbrain. Negative antibody control demonstrates no non-speciﬁc binding of the
Squares are 37.5  37.5 mm. Scale bar Z 75 mm.
The American Journal of Pathology - ajp.amjpathol.orgcolocalized with IBA-1 (microglia and macrophages)
(Figure 5, B and C) and F4/80 (macrophages) (Figure 5D). By
5 weeks of age, TLR2þ cells were frequently perivascular, had
rounded morphological characteristics, and were intensely
labeled (Figure 5C). Occasionally, colocalization with S100
was observed, indicating TLR2 expression by oligodendro-
cytes (Figure 5E). When stained simultaneously with Glut-1
(endothelial cells), TLR2 was often juxtaposed to Glut-1þ
cells but failed to colocalize, conﬁrming the perivascularprimarily by microglia and macrophages. Results represent fold changes in
ur normal brains were homogenized and qPCR was performed for each of the
copy images analyzed with Volocity 3D imaging software version 5. Three-
k-old twitcher forebrain. Image depicts large bifurcating vessel with TLR2þ/
ain. Arrowhead indicates TLR2þ/F4/80þ cells. E: Three-week-old twitcher
ebrain. Arrowhead indicates TLR2þ cell adjacent to Glut-1þ cells. G: Five-
cells are small, with few, narrow processes. HeJ: Five-week-old twitcher
secondary antibody to tissues. Error barsZ SD. **P < 0.01, ***P < 0.001.
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Figure 6 TLR2 expression was markedly increased in macrophages and
microglia. A: Ten random, nonoverlapping ﬁelds examined for three
twitcher (twi) and three normal (N) mice in the hindbrain at both 3 and 5
weeks of age. There is marked up-regulation in TLR2 in the hindbrains at
both 3 and 5 weeks of age, whereas TLR2 expression is relatively stable in
age-matched control hindbrains. TLR2 expression is most up-regulated in
the microglial/macrophage population, but occasional oligodendrocytes
also express TLR2. B: Ten random, nonoverlapping ﬁelds examined for three
twitcher and three normal mice in the forebrain at both 3 and 5 weeks of
age. TLR2 expression lags behind expression in the hindbrain. The largest
compartment expressing TLR2 is cells with morphological characteristics
most consistent with macrophages, but IBA-1 negative. Oligodendrocytes
only express TLR2 at 5 weeks of age in the forebrain. Avg, average.
Snook et alnature of TLR2 expression (Figure 5F). In the age-matched
control animals, TLR2 expression was characterized by min-
imal staining in a lightly stippled pattern on ﬂattened cells in a
perivascular location (consistent with perivascular macro-
phages) (Figure 5G). GFAPþ cells (astrocytes) and neuronal
nuclear antigen positive cells (neurons) in both twitcher mice
and normal mice never showed any TLR2 colocalization with
images analyzed (data not shown). Negative antibody controls
also demonstrated no identiﬁable immunoreactivity to any
target in twitcher mice (Figure 5, HeJ).
Quantitative analysis of immunoﬂuorescent images
(Figure 6) revealed TLR2þ cells in the normalmouse hindbrain
and forebrain. In the twitcher mouse brain at 3 weeks of age,
there was a twofold increase in total TLR2þ cells in the hind-
brain, primarily in cells that did not colocalize with IBA-1 or
S100 (Figure 6A). At 5 weeks of age, the total number of
TLR2þ cellswasnearly four times that of age-matched controls.
The forebrain also showed increases inTLR2þ cells at both time
points, including cells that did not label with typical glial
markers. On average, there was approximately one TLR2þ/
S100þ cell per 0.14 mm2 in the twitcher mouse, with the
exceptionof the3-week-old forebrains (Figure 6B).NoTLR2þ/
S100þ cells were detected in normal age-matched controls.
TLR2 was up-regulated at 2 weeks of age, coincident with
morphological evidence of microglial activation. At 2 weeks of
age, there was minimal astroglial activation, based on GFAP
immunoreactivity. In addition, microglia began to demonstrate
evidence of aggregation in the form of nodules at 2 weeks of
age. At 3 weeks of age, themicroglial nodules were surrounded
by numerous activated astrocytes. Taken together, these
demonstrate the likelihood of TLR2 leading tomacrophage and
microglial activation as early as 2 weeks of age in twitcher
hindbrains, before the activation of adjacent astrocytes.
TLR2þ Cells Reside in Areas of Demyelination among
Aggregates of PASþ Cells
IHC with 3,30-diaminobenzidine was performed to demon-
strate that TLR2 expression coincided with demyelination
and aggregates of PASþ cells (macrophages containing
storage material from incomplete GALC catabolism) in the
cerebrum and cerebellum that are characteristic of GLD.
IHC analysis demonstrated that TLR2þ cells were found
most often within white matter tracts of the hindbrain, cer-
ebellum, and cerebrum (Figure 7, A and C). TLR2þ cells
also were often located in areas that exhibited demyelination
and PASþ cells (Figure 7, B and D), consistent with being
located in areas where lesions are present in the twitcher
mouse. In this case, demyelination was demonstrated by
decreased staining with luxol fast blue.29
TLR2 Signaling Can Be Induced by Psychosine-Treated
Oligodendrocytes
To determine whether TLR2 signaling could be activated by
psychosine or dying oligodendrocytes, a TLR2 reporter390assay was used that secretes alkaline phosphatase when NF-
kB and AP-1 are activated. When the reporter cells were
exposed to psychosine at concentrations ranging from 100
mg/mL to 1 ng/mL, there was no measurable increase in
alkaline phosphatase production compared with HEK-null
cells (negative control) (Figure 8A). The same cells
responded appropriately to PAM3CSK4 (a TLR2 ligand),
demonstrating the ability to respond when stimulated
through TLR2. Psychosine also caused a morphological
change in the treated cells: they appeared shrunken, with no
evidence of replication or cell growth on the culture plate.ajp.amjpathol.org - The American Journal of Pathology
Figure 8 TLR2 signaling was induced by psychosine-treated oligoden-
drocytes. A: Fold changes in HEK-TLR2 and HEK-null2 treated with psy-
chosine at concentrations between 0 and 100 mg/mL. B: HEK-TLR2 and
HEK-null2 cells treated with galactocerebroside in concentrations between
0 and 100 mg/mL. C: HEK-TLR2 and HEK-null2 reporter cells treated with
conditioned medium from psychosine-treated oligodendrocytes in con-
centrations between 0 and 100 mg/mL. All experiments were repeated three
times with two replicates per treatment. Fold values were calculated by
dividing the spectrophotometry reading of HEK-TLR2 cells by the reading
for HEK-null2 cells. Error bars Z SD. *P < 0.05.
Figure 7 TLR2 was expressed in demyelinated areas and coincided with
PASþ cells. A: TLR2 is immunoreactive in the white matter tracts of the
cerebellum. The highly nucleated areas near the top and bottom of the
image represent the molecular layer of the cerebellum. The less cellular area
in the center represents a white matter tract. B: In the same anatomical
region as identiﬁed in A, arrowheads identify PASþ cells scattered
throughout. This area also demonstrates moderate to marked demyelin-
ation based on decreased luxol fast blue (LFB) staining in the area. C: White
matter tracts in the cerebrum express TLR2þ cells most frequently. D: White
matter tracts in the cerebrum demonstrate demyelination and PASþ cell
accumulation. E and F: Normal white matter tracts in the cerebellum and
cerebrum, respectively. Both areas show normal levels of myelination and
no PASþ cells. Scale bar Z 50 mm.
Early Events in GLDTreating HEK-TLR2 cells with GalCer also did not induce
TLR2 signaling (Figure 8B). However, when HEK-TLR2
cells were exposed to conditioned medium from oligoden-
drocytes cultured with 100 mg/mL psychosine, there was a
signiﬁcant fold change in TLR2 signaling over HEK-null
cells (Figure 8C). PAM3CSK4 and TNF-a were used as
positive controls to demonstrate the ability of HEK-TLR2
and HEK-null cells to respond to stimuli activating the
TLR2 and extra-TLR pathways, respectively. These results
show that as oligodendrocytes undergo cell death from
psychosine treatment, they release a TLR2 ligand that ac-
tivates the TLR2 signaling pathway and leads to NF-kB and
AP-1 activation.
Cytokine/Chemokine Expression Lags Behind TLR2
Up-Regulation
Determining when cytokines and chemokines are up-
regulated during the course of disease is important to
establish the chronology of disease progression and whether
they are the cause or effect of inﬂammatory activation. IL-6,The American Journal of Pathology - ajp.amjpathol.orgCCL2 (monocyte chemotactic protein-1), CXCL10 (IP-10),
and CXCL1 (keratinocyte chemoattractant; gro-a) all
exhibited moderate to marked progressive increases in
expression during the course of disease (Figure 9). None of
these cytokines and chemokines demonstrated a signiﬁcant
increase in expression before 3 weeks of age in either the
forebrain or the hindbrain/cerebellum; this was 1 week after
elevations in TLR2 expression were observed (Figure 5A).
CXCL1 and CXCL10 had the earliest increase in expression
levels at 3 weeks of age in the hindbrain. They did not increase
signiﬁcantly until 4 and 5 weeks, respectively, in forebrains of
twitcher mice. IL-6 and CCL2 also demonstrated signiﬁcant391
Snook et alincreases in expression levels, but not until 4 and 5 weeks of
age in the hindbrain, respectively.
Additional chemokines that became elevated in the
twitcher mouse during the course of disease were CCL3,
CXCL9 (monokine induced by IFN-g), CCL5 (regulated on
activation normal T cell expressed and secreted), CCL11,
and leukemia inhibitory factor (Supplemental Figure S1).
Each of these increased signiﬁcantly between 3 and 4 weeks
of age in the hindbrain and cerebellum and lagged behind by
approximately a week in the forebrain. Vascular endothelial
growth factor decreased during the course of GLD in
twitcher mice (data not shown).
In addition to the cytokines and chemokines previously
mentioned, cytokines associated with the early immune
response were tested: IL-1a, IL-1b, TNF-a, and IFN-g. AllFigure 9 Cytokine and chemokine up-regulation lags behind TLR2 up-regulat
each age group for both the hindbrain and forebrain. Samples were prepared in du
CXCL1, and CCl2 in the hindbrain and forebrain. Expression levels of IL-6, CXCL10,
twitcher mice, ﬁrst in the hindbrain and then in the forebrain approximately a w
demonstrated for TLR2. In addition, TNF-a, IFN-g, IL-a, and IL-b did not demo
twitcher mice. TNF-a only showed minimal up-regulation during the course of a twi
evidence of up-regulation compared with age-matched controls. Error bars Z SD
392demonstrated changes in expression between 2 and 5 weeks
of age in the twitcher mouse. However, only TNF-a
demonstrated any degree of signiﬁcant expression compared
with age-matched controls, and only increased to a signiﬁ-
cant level in the hindbrain at 3 weeks of age, but never
increased signiﬁcantly in the forebrain (Figure 9).
These ﬁndings support the hypothesis that TLRs and, spe-
ciﬁcally, TLR2 may serve as an initiator in the inﬂammatory
proﬁle of twitcher mouse brains. Based on the qPCR data,
TLR2 was up-regulated as early as 2 weeks of age in the
twitcher hindbrain, coinciding with morphological evidence
of microglial/macrophage activation. However, the earliest
cytokine/chemokine elevations observed in this study were at
3 weeks of age in the hindbrain. Cytokine/chemokine
expression is often closely associated with the transcriptionion. Four twitcher (twi) mice and three normal (N) mice were evaluated at
plicate for the cytokine/chemokine assay. Expression levels of IL-6, CXCL10,
CXCL1, and CCL2 all increased after previous inﬂammation in the brains of
eek later. This slight lag correlates well with the previous expression curve
nstrate any increase before the up-regulation of TLR2 in the hindbrain of
tcher mouse’s lifespan, whereas the other cytokines never demonstrated any
. *P < 0.05, **P < 0.01, and ***P < 0.001.
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factors as the end point for their signaling pathway. The lag in
cytokine/chemokine elevation behind TLR2 up-regulation is
consistent with the possibility of TLR2 signaling contributing
to the inﬂammatory milieu in GLD.
Discussion
The results of this study describe novel pathological ﬁndings
related to the early events involved in the pathogenesis of
GLD. The earliest change we identiﬁed was up-regulation of
TLR2 on macrophages and microglia as early as 2 weeks of
age in the hindbrain and cerebellum of twitcher mice. This
occurred concurrent with the activation of microglia and
resident macrophages. Astrocytes only became activated
subsequent to formation of discrete microglial nodules.
Subsequently, astrocytes were diffusely activated by 5 weeks
of age when they no longer appear to be associated with
microglial nodules.
Glial nodules or scars are most often presumed to be
residual to resolution of disease or a quiescent state of the
disease. In the case of GLD, these glial nodules appeared to
be initiating foci that lead to activation of neighboring glial
cells and inﬂammation in the brain. The concept of a glial
nodule as a driver of cellular activation and inﬂammatory
induction is novel and not completely understood. Further
studies examining glial cell activation are warranted to
clarify the cross talk that enables such interactions to occur.
In the context of GLD, further studies should examine
microglial TLR expression in spatial relationship to nearby
oligodendrocytes undergoing apoptosis or necrosis.
The ability to elicit a TLR2 signaling response with
psychosine-treated oligodendrocytes may represent a mech-
anism for cellular activation in vivo. Because oligodendro-
cytes accumulate psychosine in vivo from the inability to
properly catabolize GALC, they undergo apoptosis.3,10e14 As
they die, they may release an endogenous ligand for TLR2
that ultimately leads to macrophage and microglial activation,
astrocyte activation, and cytokine and chemokine up-
regulation. A recent study demonstrated such a possibility
in that products of apoptosis can be identiﬁed through cross-
reactivity with lipopolysaccharide and, ultimately, activation
through TLR4.42 A similar mechanism may occur in this
instance. Future studies are warranted to determine what
causes TLR2 up-regulation in GLD. Possible causes of TLR2
up-regulation would be S10043 or some other damage-
associated molecular pattern that is released on oligoden-
drocyte death.42 Proteomic analysis of oligodendrocytes
undergoing apoptosis may yield valuable information about
potential causes of innate immune up-regulation.
Previous studies have raised the question of what leads to
the activation of glial cells and their subsequent secretion of
cytokines and chemokines in GLD.5,8 Our study elucidated a
potential series of steps leading to the ultimate up-regulation of
cytokines/chemokines and the recruitment of monocytes/
macrophages to affected areas. Based on existing data and theThe American Journal of Pathology - ajp.amjpathol.orgresults of this study, the proposed sequence of events leading
to the ﬁnal pathological outcomes of this disease are as fol-
lows: i) oligodendrocytes cannot effectively catabolize GalCer
due to absence of GALC, ii) psychosine accumulates in oli-
godendrocytes, iii) oligodendrocytes undergo apoptosis,
leading to axonal demyelination, iv) a TLR ligand is released
from oligodendrocytes, which leads to TLR2 signaling and
macrophage/microglial activation, v) microglia form an early
glial nodule, vi) astrocytes surrounding microglial nodules
become activated, forming a mature glial nodule, and vii)
cytokines/chemokines are released and inﬂammation con-
tinues to spread and increase.
Understanding the role of the innate immune system in
up-regulation and activation of inﬂammatory cells is
important to help identify potential targets for treatment.
TLRs are important in inducing transcription of cytokines
and chemokines39,44e48 but are also important in embryonic
development and regeneration of the CNS.25,49e51 Under-
standing how TLR2 activation affects the pathological
characteristics of the brains of individuals with GLD is
important to understanding how to modify expression of the
molecule and generate an effective treatment.
Because TLR up-regulation leads to cytokine and chemo-
kine up-regulation in vivo, it is important to understand the
chronological relationship of TLR up-regulation to cytokine
and chemokine expression. Of the 32 cytokines and chemo-
kines tested in this study, four of them (IL-6, CXCL1,
CXCL10, and CCL2) demonstrated marked, signiﬁcant up-
regulation as early as 3 weeks of age. IL-6 is commonly
associated with induction of the innate immune system.46,52,53
It has a wide range of properties, including induction of
inﬂammation,46,54e56 and can affect neurogenesis.56,57 In
GLD, previous studies have shown IL-6 to be produced by
bothmicroglia and astrocytes,17 and crossing a twitcher mouse
with an IL-6 knockout mouse led to more severe pathological
characteristics than the IL-6 competent twitcher mouse.58 It
would seem that IL-6 plays an important protective role in the
pathogenesis of the disease, but it is not clear how IL-6 is up-
regulated or exactly how IL-6 is protective.
When considering CXCL1 in the context of GLD, it is
helpful to understand that this molecule is most commonly
associated with chemotaxis of neutrophils.55 In the case of
GLD, there are no neutrophils or granulocytes present in the
brain at any point during disease progression. According to
other studies, CXCL1 and its receptor, CXCR2, can also
have effects on oligodendrocyte progenitor maturation and
migration and are produced at high levels at speciﬁc time
points within the developing fetal brain.59e61 Another study
demonstrated a protective ability to remyelinate neurons in
the brains of mice engineered to overexpress CXCL1.62
Given the high levels of CXCL1 in GLD, it would seem
that CXCL1 may be produced in an effort to replace the
dying oligodendrocytes with new oligodendrocytes derived
from resident oligodendrocyte progenitor cells.
Similarly, CXCL10 is most often associated with
lymphocyte chemotaxis, yet there are no recognizable393
Snook et allymphocytes in the twitcher brain. Both CXCL9 and
CXCL10 are ligands for the CXCR3 receptor, which is
present on many of the resident glial cells in resting and
pathological conditions.63e65 It may be that CXCR3 and
CXCL10 have functions in the brain that are distinct from
their roles in lymphocyte chemotaxis.
CCL2 (monocyte chemotactic protein-1) is most often
associated with monocyte recruitment.66 In the case of
GLD, there are numerous monocytes recruited to the brain
during the disease process, presumably recruited by CCL2.
In a previous study of GLD in macaques, CCL2 was pro-
duced primarily by astrocytes.7
Finally, it is important to mention the lack of TNF-a
and IFN-g elevation early in the course of GLD progres-
sion in the twitcher mouse. Both of these cytokines are
associated with activation of the innate immune system
and activation of signaling pathways associated with
further up-regulation of other cytokines and chemokines.
Neither of these cytokines was elevated before the
increased expression of TLR2. This is in accordance with
previous studies that demonstrated low TNF-a levels.18 In
addition, when twitcher mice are crossed to TNF receptor
1 knockout mice, the progeny demonstrate no signiﬁcant
change in phenotype,67 leading to the conclusion that
TNF-a does not appear to play a primary role in pro-
gression of disease.
The data support a mechanism of cellular activation and
a sequence of events not previously described in the
pathogenesis of globoid cell leukodystrophy. Earlier
studies focused only on macrophages and microglia as
they arrive in the CNS or begin to express markers of
activation. This study indicates that microglia may be the
primary cells of activation early in the disease process.
Although it is possible that TLR2 could be a marker of
inﬂammatory activation on microglia, its up-regulation
occurs before the detection of all other markers of acti-
vation examined in this study, and occurs concurrently
with morphological evidence of microglial and macro-
phage activation in the murine CNS. In addition, TLR2
signaling could be induced through a product released by
oligodendrocytes when they are treated with psychosine.
Phenotypic studies crossing TLR2 knockout mice to
twitcher mice could be useful in further delineating the
role of TLR2 in the progression of disease. Discovering
that TLR2 may be the primary driver of inﬂammatory
changes in the twitcher mouse could result in more
effective, targeted treatments for GLD.
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